Phase 2 Breast Cancer Trial, Recruiting NCT05759546 Sponsor: Fudan University Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT05759546
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 to 75 years old
  • People with a confirmed breast cancer type known as HR-positive, HER2-negative (meaning the cancer tests positive for hormone receptors but negative for a protein called HER2, based on specific lab measurements)
  • People whose cancer has been identified as a specific breast cancer subtype called "SNF-3," confirmed by a specialist pathology lab at Fudan University Cancer Hospital
  • People whose cancer is either locally advanced (not able to be fully treated with local treatments) or has spread to other parts of the body
  • People whose cancer can be measured on scans, or who have certain types of bone involvement that may not be measurable in the usual way
  • People whose bone marrow is working well enough, shown by blood test results meeting minimum levels for white blood cells, platelets, and haemoglobin
  • People who have not previously had chemotherapy or targeted therapy for their advanced or spread cancer
  • People whose liver and kidney function tests meet the required levels (confirm with trial site for specific values)
  • People with a general health performance score of 2 or less on a standard medical scale, and a life expectancy of at least 3 months
  • People who are willing to participate, have signed a consent form, and have agreed to attend follow-up appointments

Who may not be able to join:

  • People who have already received chemotherapy, radiotherapy, immunotherapy, or major surgery to treat their advanced or spread cancer
  • People who have brain or spinal cord cancer spread that is causing symptoms, has not been treated, or is getting worse, particularly if medication is needed to manage symptoms
  • People who have had significant heart problems in the past 6 months, such as heart failure, chest pain from the heart, a heart attack, or serious irregular heartbeat
  • People who are currently pregnant or breastfeeding
  • People who have had another cancer diagnosis in the past five years (with the exception of certain fully treated skin cancers or early-stage cervical cell changes)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-021-64175590

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 February 2023
Est. completion
1 November 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

PFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov